Projects per year
Personal profile
Headline
ASSOCIATE PROFESSOR Medicine, Clinical Immunology
Fingerprint
Dive into the research topics where Paula Busse is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Depression in Older Asthmatics: Understanding Inflammatory and Behavioral Pathways
Wisnivesky, J. J. P., Busse, P., Feldman, J. M., Feldman, J. J. M., Busse, P. P. J. & Wisnivesky, J. P.
National Heart, Lung, and Blood Institute
1/06/19 → 30/04/23
Project: Research
-
Childhood Asthma in Urban Settings
Busse, P., Bunyavanich, S. & Wisnivesky, J. P.
National Institute of Allergy and Infectious Diseases
15/04/21 → 31/03/22
Project: Research
-
Airway Cellular and Cytokine Profiles in Older Patients with Asthma
National Institute of Allergy and Infectious Diseases
8/08/13 → 31/07/15
Project: Research
-
Contribution of TNF-alpha to mucus cell production in asthma
Busse, P. & Busse, P. J.
National Institute of Allergy and Infectious Diseases
1/07/06 → 31/05/11
Project: Research
-
Cognition, symptom perception, and medication non-adherence in older adults with asthma
Becker, J. H., Feldman, J. M., Arora, A., Busse, P. J., Wisnivesky, J. P. & Federman, A. D., 2022, In: Journal of Asthma. 59, 3, p. 607-615 9 p.Research output: Contribution to journal › Article › peer-review
4 Scopus citations -
Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
for the HELP OLE Investigators, Mar 2022, In: Allergy: European Journal of Allergy and Clinical Immunology. 77, 3, p. 979-990 12 p.Research output: Contribution to journal › Article › peer-review
Open Access12 Scopus citations -
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
Craig, T., Magerl, M., Levy, D. S., Reshef, A., Lumry, W. R., Martinez-Saguer, I., Jacobs, J. S., Yang, W. H., Ritchie, B., Aygören-Pürsün, E., Keith, P. K., Busse, P., Feuersenger, H., Pawaskar, D., Jacobs, I., Pragst, I. & Doyle, M. K., 5 Mar 2022, In: The Lancet. 399, 10328, p. 945-955 11 p.Research output: Contribution to journal › Article › peer-review
12 Scopus citations -
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade
Busse, P. & Kaplan, A., Mar 2022, In: Journal of Allergy and Clinical Immunology: In Practice. 10, 3, p. 716-722 7 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., Aberer, W., Ansotegui, I. J., Aygören-Pürsün, E., Banerji, A., Bara, N. A., Boccon-Gibod, I., Bork, K., Bouillet, L., Boysen, H. B., Brodszki, N., Busse, P. J., Bygum, A., Caballero, T., Cancian, M., Castaldo, A. J., Cohn, D. M., Csuka, D., & 39 others, Mar 2022, In: World Allergy Organization Journal. 15, 3, 100627.Research output: Contribution to journal › Article › peer-review
Open Access10 Scopus citations
Press/Media
-
EMPOWER reflects efficacy, safety of lanadelumab for HAE in real world
7/03/22
1 item of Media coverage
Press/Media
-
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
27/02/22 → 2/03/22
39 items of Media coverage
Press/Media
-
-Takeda - Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients
1/03/22
2 items of Media coverage
Press/Media
-
Takeda: Interim Phase 4 Data Support TAKHZYRO (lanadelumab) as an Effective Treatment
28/02/22
1 item of Media coverage
Press/Media